X

Trial Profile

Phase 1 Open-Label Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Memory cytokine enriched natural killer cell therapy-ImmunityBio (Primary) ; Nogapendekin alfa inbakicept (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man; Proof of concept
Acronyms QUILT 3.076
Sponsors ImmunityBio

Most Recent Events

18 Oct 2024 Planned End Date changed from 31 Dec 2024 to 31 Mar 2025.
18 Oct 2024 Planned primary completion date changed from 21 Jun 2024 to 31 Mar 2025.
13 Jun 2023 Planned number of patients changed from 30 to 50.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com